This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Heteroclitic CALRMUT peptides elicited a CD8+ T cell response in patients, unlike native peptides.
Why it matters
This research highlights a potential new approach to cancer vaccination that could improve outcomes for patients with specific genetic mutations.
How the study worked
The study analyzed MHC-I allele frequencies in patients and tested immune responses to modified peptides in human samples and mouse models.
What this study cannot tell us
The study primarily focused on specific patient cohorts, which may limit the generalizability of the findings.
Read the original research
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Science translational medicine, 14(649), eaba4380
Citation
Gigoux, Mathieu; Holmström, Morten O; Zappasodi, Roberta; Park, Joseph J; Pourpe, Stephane; Bozkus, Cansu Cimen; Mangarin, Levi M B; Redmond, David; Verma, Svena; Schad, Sara; George, Mariam M; Venkatesh, Divya; Ghosh, Arnab; Hoyos, David; Molvi, Zaki; Kamaz, Baransel; Marneth, Anna E; Duke, William; Leventhal, Matthew J; Jan, Max; Ho, Vincent T; Hobbs, Gabriela S; Knudsen, Trine Alma; Skov, Vibe; Kjær, Lasse; Larsen, Thomas Stauffer; Hansen, Dennis Lund; Lindsley, R Coleman; Hasselbalch, Hans; Grauslund, Jacob H; Lisle, Thomas L; Met, Özcan; Wilkinson, Patrick; Greenbaum, Benjamin; Sepulveda, Manuel A; Chan, Timothy; Rampal, Raajit; Andersen, Mads H; Abdel-Wahab, Omar; Bhardwaj, Nina; Wolchok, Jedd D; Mullally, Ann; Merghoub, Taha. (2022). Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.. Science translational medicine, 14(649), eaba4380. https://doi.org/10.1126/scitranslmed.aba4380